SKYE
Skye Bioscience, Inc.
1.70$
-1.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.0% | 97.6% | 99.7% | 99.7% | 97.9% | 97.3% | 97.3% | 97.0% | 96.6% | 95.7% | 95.6% | 99.3% | |
| 32.9% | 10.5% | 87.9% | 84.9% | 82.7% | 94.0% | 71.6% | 45.7% | 44.6% | 20.8% | 42.0% | 73.1% | |
| 32.9% | 10.5% | 87.9% | 84.9% | 82.7% | 94.0% | 91.4% | 93.1% | 85.5% | 90.9% | 88.1% | 91.2% | |
| 5.5% | 1.3% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | |
| 59.5% | -6.3% | 11.1% | 14.1% | – | – | – | – | – | – | – | – | |
| 2.0% | – | – | – | – | – | – | – | – | – | – | – | |
| 89.1% | 117.9% | 16.8% | 16.6% | 7.0% | 6.3% | 8.6% | 16.3% | 20.5% | 29.3% | 53.6% | 104.5% | |
| 87.9% | 116.4% | 16.7% | 16.4% | 6.9% | 6.0% | 8.2% | 15.9% | 20.2% | 29.0% | 53.6% | 104.5% | |
| 27.1% | 37.2% | 4.9% | 5.7% | 0.1% | 0.3% | 0.3% | 0.4% | 0.5% | 0.7% | 1.6% | 0.3% | |
| 10.5% | 8.0% | 1.2% | 1.2% | 1.0% | 0.8% | 2.6% | 6.2% | 6.8% | 7.2% | 20.3% | 38.8% | |
| 10.9% | -17.9% | 83.2% | 83.4% | 93.0% | 93.7% | 91.4% | 83.7% | 79.5% | 70.7% | 46.4% | -4.5% | |
| -640.6% | -874.2% | -115.4% | -134.4% | -148.7% | -180.0% | -219.2% | -306.1% | -417.3% | -660.0% | -1,026.9% | -1,904.8% | |
| 6,226.2% | 12.9% | 3.7% | 5.5% | 6.0% | 6.9% | 7.6% | 9.5% | 12.0% | 17.5% | 25.5% | 45.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.